Research Reports in Clinical Cardiology最新文献_第10页

Cardiovascular risk prediction: the old has given way to the new but at what risk-benefit ratio? 心血管风险预测:老的已经让位于新的，但是风险收益比是多少?

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-10-14 DOI: 10.2147/RRCC.S44909

J. Yeboah

引用次数: 0

Heart failure self-care interventions to reduce clinical events and symptom burden 心衰自我护理干预减少临床事件和症状负担

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-09-23 DOI: 10.2147/RRCC.S48424

M. McGreal, Maureen J Hogan, Colleen Walsh-Irwin, Nancy J. Maggio, C. Jurgens

引用次数: 24

Current developments in the use of transcatheter aortic valve implantation in high-risk patients 经导管主动脉瓣植入术在高危患者中的应用进展

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-09-23 DOI: 10.2147/RRCC.S40391

V. Pera, S. Pasupati

引用次数: 0

Relationship between plasma apolipoprotein B concentrations and LDL particle number 血浆载脂蛋白B浓度与LDL颗粒数的关系

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-09-18 DOI: 10.2147/RRCC.S65976

Pamela B. Morris, Kellie Mclain, H. Malave, James Underberg, Ngoc-Anh Le, Michael D. Shapiro, D. Winegar, R. Pourfarzib

{"title":"Relationship between plasma apolipoprotein B concentrations and LDL particle number","authors":"Pamela B. Morris, Kellie Mclain, H. Malave, James Underberg, Ngoc-Anh Le, Michael D. Shapiro, D. Winegar, R. Pourfarzib","doi":"10.2147/RRCC.S65976","DOIUrl":"https://doi.org/10.2147/RRCC.S65976","url":null,"abstract":"Many subjects with relatively normal, or even optimal, levels of low-density lipoprotein cholesterol (LDL-C) have increased atherogenic lipoprotein particle concentrations (apolipoprotein B (apoB) and LDL particle number (LDL-P) determined by nuclear magnetic resonance spec- troscopy (NMR)). Numerous analyses have demonstrated that apoB and LDL-P predict the risk of future cardiovascular events more robustly than LDL-C, as estimated using the Friedewald equation. Little is known about the relationship between an individual's apoB and LDL-P level, and whether the relationship is comparable at different levels of LDL-C. The aim of this study was to examine the correlation between plasma apoB and LDL-P levels and specifically to evaluate the heterogeneity of LDL-P at low levels of apoB (, the 20th population percentile (78 mg/dL)). Data were derived from a group of consecutive patients added to a large, single laboratory database (LipoScience, Inc.) during a 1-week period in which a standard lipid profile, apoB, and LDL-P levels were available. When risk categories were assigned to the subjects using the Framingham Offspring Study's population percentiles for apoB and LDL-P, there was good agreement between the two measures when LDL-C levels were high ($160 mg/dL). However, among individuals with low LDL-C and apoB, NMR analysis could identify a subgroup of individuals with potentially","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"30 1","pages":"237-242"},"PeriodicalIF":0.4,"publicationDate":"2014-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S65976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68474741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging catheter technologies for percutaneous transluminal coronary angioplasty 当前和新兴的经皮冠状动脉血管成形术导管技术

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-09-10 DOI: 10.2147/RRCC.S47217

P. Prashant

引用次数: 9

ventricular assist devices for heart failure: a focus on patient selection and complications 心力衰竭的心室辅助装置:患者选择和并发症的重点

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-09-09 DOI: 10.2147/RRCC.S48886

M. Cipriani, V. Simone, L. D’angelo, E. Perna, M. Lilliu, V. Bovolo, F. Oliva, M. Frigerio

{"title":"ventricular assist devices for heart failure: a focus on patient selection and complications","authors":"M. Cipriani, V. Simone, L. D’angelo, E. Perna, M. Lilliu, V. Bovolo, F. Oliva, M. Frigerio","doi":"10.2147/RRCC.S48886","DOIUrl":"https://doi.org/10.2147/RRCC.S48886","url":null,"abstract":"Heart transplantation represents the \"gold standard\" for the treatment of patients with end-stage heart failure, but remains challenged by inadequate donor supply, finite graft survival, and long-term complications arising from immunosuppressive therapy. In addition, a lot of patients waiting for a heart transplant experience clinical deterioration, and other patients become ineligible to undergo this treatment due to their age or relevant comorbidities. Left ventricular assist devices have emerged as a valid therapeutic option for advanced heart failure. In recent years, we have seen significant advances not only in the technologies available, but also in patient selection, indications for use, and management after implantation. Consequently, there has been an increase in the number of implants and an improvement in the survival rate and quality of life for these patients. At the same time, there are new challenges on the horizon. Patient selection is a difficult process, based on clinical and imaging parameters and risk scores, and more data are needed to refine patient selection criteria and the timing of the implant. Left ventricular assist device-related complications are still a serious problem, causing adverse events and hospital readmissions. Continuous progress in the development of these implantable devices, such as a further reduction in size and hopefully the abolition of the external driveline, will probably make ventricular assist devices an option also for less advanced stages of heart failure. Here, we discuss the current indications for left ventricular assist device implantation, patient selection criteria, and the most frequent complications associated with these devices.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"199-211"},"PeriodicalIF":0.4,"publicationDate":"2014-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S48886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68473957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cardiac function and hypertension in patients with obstructive sleep apnea 阻塞性睡眠呼吸暂停患者的心功能和高血压

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-08-28 DOI: 10.2147/RRCC.S52232

A. Bertolami, Carolina C. Gonzaga, C. Amodeo

{"title":"Cardiac function and hypertension in patients with obstructive sleep apnea","authors":"A. Bertolami, Carolina C. Gonzaga, C. Amodeo","doi":"10.2147/RRCC.S52232","DOIUrl":"https://doi.org/10.2147/RRCC.S52232","url":null,"abstract":"Cardiovascular disease is one of the major causes of death worldwide. Among its risk factors, obstructive sleep apnea (OSA) is a common but still underestimated condition. OSA often coexists and interacts with obesity, sharing multiple pathophysiological mechanisms and subsequent cardiovascular risk factors, such as type 2 diabetes, dyslipidemia, systemic inflam - mation, and in particular hypertension. There is also evidence suggesting an increased risk of arrhythmia, heart failure, renal failure, acute myocardial infarction, stroke, and death. OSA is characterized by recurrent episodes of partial (hypopnea) or complete interruption (apnea) of breathing during sleep due to airway collapse in the pharyngeal region. The main mechanisms linking OSA to impaired cardiovascular function are secondary to hypoxemia and reoxygenation, arousals, and negative intrathoracic pressure. Consequently, the sympathetic nervous and the renin-angiotensin-aldosterone systems may be overestimulated, and blood pressure increased. Resistance to treatment for hypertension represents a growing issue, and given that OSA has been recognized as the major secondary cause of resistant hypertension, clinical investigation for apnea is mandatory in this population. Standard diagnosis includes polysomnography, and treatment for OSA should include control of risk factors for cardiovascular disease, including obesity. So far, continuous positive airway pressure is the treatment of choice for OSA, impacting positively on blood pressure goals; however, the impact on long-term follow-up and on cardio- vascular disease should be better assessed.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"27 1","pages":"189-197"},"PeriodicalIF":0.4,"publicationDate":"2014-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S52232","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68474262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Clinical utility of ivabradine in cardiovascular disease management: current status 伊伐布雷定在心血管疾病治疗中的临床应用现状

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-08-26 DOI: 10.2147/RRCC.S46468

G. Rosano, C. Vitale, I. Spoletini, M. Volterrani

引用次数: 4

Current treatments for acute heart failure: focus on serelaxin 目前急性心力衰竭的治疗:重点是血清松弛素

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-07-16 DOI: 10.2147/RRCC.S44470

R. Bennett

{"title":"Current treatments for acute heart failure: focus on serelaxin","authors":"R. Bennett","doi":"10.2147/RRCC.S44470","DOIUrl":"https://doi.org/10.2147/RRCC.S44470","url":null,"abstract":"Acute heart failure remains an enormous health concern worldwide, and is a major cause of death and hospitalization. In spite of this, the treatment strategies for acute heart failure have remained largely unchanged for the past 2 decades. Several large randomized, placebo- controlled clinical trials have recently been conducted to attempt to improve the treatment and outcomes of acute decompensated heart failure. Some studies, including the EVEREST (tolvaptan) and ASCEND (nesiritide) showed efficacy at relieving early symptoms, but failed to improve long-term outcomes. Others, including PROTECT (rolofylline) and ASTRONAUT (aliskiren) showed little benefit in the relief of early symptoms or long-term outcomes. The recent RELAX-AHF studies using serelaxin, a recombinant form of relaxin, have shown considerable promise. Importantly, serelaxin improved congestion (dyspnea) and other early targets of acute decompensated heart failure treatment, but also improved mortality at 180 days. The purpose of this review is to provide an overview of current treatment strategies for acute decompensated heart failure, and a discussion of the recent clinical trials, with an emphasis on","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"5 1","pages":"169-182"},"PeriodicalIF":0.4,"publicationDate":"2014-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S44470","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68472600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Optimal treatment of chronic angina in patients with type 2 diabetes mellitus 2型糖尿病患者慢性心绞痛的最佳治疗

IF 0.4

Research Reports in Clinical Cardiology Pub Date : 2014-07-07 DOI: 10.2147/RRCC.S46025

H. Kaur, K. Sandhu, A. Jabbar, A. Zaman

{"title":"Optimal treatment of chronic angina in patients with type 2 diabetes mellitus","authors":"H. Kaur, K. Sandhu, A. Jabbar, A. Zaman","doi":"10.2147/RRCC.S46025","DOIUrl":"https://doi.org/10.2147/RRCC.S46025","url":null,"abstract":"Type 2 diabetes mellitus (T2DM) trebles the risk of developing coronary artery disease (CAD); once CAD has developed, the risk of acute coronary syndromes (ACS) and clinical risk associated with a coronary event, both double in diabetic patients. Patients with T2DM have more extensive CAD and present at a younger age; therefore, identification and management of chronic angina in these patients presents an opportunity to limit both cardio- vascular symptoms and adverse outcomes. This article reviews the role of screening and treat- ment for chronic angina in patients with T2DM. There is a strong evidence base for modifying lifestyle as a way of reducing adverse cardiovascular outcomes in the diabetic population and this article reviews evidence of lifestyle modification as an important and necessary adjunct to pharmacologic intervention. Management of chronic stable angina is addressed by looking at treatments that reduce ischemic symptoms and those that reduce adverse cardiovascular outcomes. Trials specific to the diabetic population are limited, with information largely obtained from the diabetic subgroup analysis of large intervention trials. The growing diabetic population with increased propensity to cardiovascular disease mandates trials specifically in this patient population. Revascularization in patients with diabetes is associated with more complications than in the non-diabetic population. Recent trials specific to this population suggest surgical revascularization to be associated with better long-term outcomes and therefore, this article reviews the evidence for the optimal mode of revascularization in this population.","PeriodicalId":42306,"journal":{"name":"Research Reports in Clinical Cardiology","volume":"26 1","pages":"155-167"},"PeriodicalIF":0.4,"publicationDate":"2014-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRCC.S46025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68473864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2